Resources

Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a potential first-in-class treatment for osteoarthritis (OA), today presented new data from its 518-patient Phase II trial of LEVI-04 (ClinicalTrials.gov ID: NCT05618782) at the American College of Rheumatology's annual meeting, ACR Convergence 2026, being held from 6 to 11 November in Orlando, Florida.

Coulter Partners, the global expert building leadership teams for Health, Science, and Technology innovation businesses, successfully led a search assignment for MitoRx Therapeutics (“MitoRx”) and is pleased to announce the placement of Neil Anderson, Ph.D., as Chief Business Officer.

Oyster Therapeutics, formerly Kesmalea Therapeutics, has raised $60 million in Series A financing to advance a new generation of targeted protein degraders for neurodegenerative diseases. The financing will support the company’s lead oral, brain-penetrant tau degrader toward clinical development and further advance its proprietary SELFTAC® platform.

AbbVie expansion; NICE and MHRA; huge biotech fundraising; clinical trial recruitment; pension investment; International Investor Summit; and bioProcessUK

Matthew Durdy to retire as CEO of Cell and Gene Therapy Catapult after fifteen years shaping UK advanced therapies

Press release for PETG PharmaTainer product launch

Discovery Park, Kent’s science and innovation hub, has launched the eighth edition of its Discovery Spark accelerator programme, welcoming 10 startups to its campus in Sandwich.

Pioneer Group – the company leading the regeneration of the Grafton Centre – has announced Cambridge-based Envision Health as the winner of its first accelerator programme, aimed at supporting the city’s early-stage tech companies.

Chris Molloy on the Budget; Wellcome Genome Campus; AbbVie; engagement with NICE and MHRA; rare conditions policy; and clinical trials

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.

Chris Molloy, CEO of the BioIndustry Association (BIA), responds to Budget 2026

AI-powered analysis of Phase 3 CHARM trial suggests that Brainomix non-contrast CT (NCCT) technology may help identify severe stroke patients more likely to benefit from CIRARA, supporting more precise patient selection and the design of future stroke trials.

One North Quay, a 23-storey science, technology and innovation campus at Canary Wharf, has reached its full height.

This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.

Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

Q3 UK biotech financing; Budget calls; early-stage funding gap; faster clinical trials; connecting Government and industry; digital and AI skills webinar